1.99
+0.14(+7.57%)
Currency In USD
Address
7801 North Capital of Texas Highway
Austin, TX 78731
United States of America
Phone
512 501 2444
Sector
Healthcare
Industry
Biotechnology
Employees
30
First IPO Date
July 14, 2000
| Name | Title | Pay | Year Born |
| Mr. Richard Jon Barry | Chief Executive Officer, President & Director | 319,375 | 1959 |
| Mr. R. Christopher Cook J.D. | Chief Operating & Legal Officer | 425,000 | 1964 |
| Mr. Eric J. Schoen | Chief Financial Officer | 725,000 | 1968 |
| Jaren Landen | Chief Clinical Development Officer | 0 | N/A |
| Dr. Angélique Bordey Ph.D. | Senior Vice President of Neuroscience | 0 | N/A |
| Dr. George Thornton Ph.D. | Senior Vice President of Technology | 0 | N/A |
| Mr. Michael Zamloot | Senior Vice President of Technical Operations | 0 | N/A |
| Dr. Michael Marsman Pharm.D. | Senior Vice President of Regulatory Affairs | 0 | N/A |
| Ms. Freda Nassif | Chief Business Officer & Chief Commercial Officer | 0 | 1976 |
| Mr. Jack Moore Ph.D. | Senior Vice President of Clinical Development | 0 | N/A |
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.